vs
Side-by-side financial comparison of Allstate (ALL) and Incyte (INCY). Click either name above to swap in a different company.
Incyte is the larger business by last-quarter revenue ($1.3B vs $922.0M, roughly 1.4× Allstate). Allstate runs the higher net margin — 266.6% vs 23.8%, a 242.8% gap on every dollar of revenue. On growth, Incyte posted the faster year-over-year revenue change (20.9% vs 7.2%). Over the past eight quarters, Incyte's revenue compounded faster (10.4% CAGR vs -75.8%).
The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. The company operates through Allstate Protection; Protection Services; Allstate Health and Benefits; and Run-off Property-Liability segments. The Allstate Protection segment offers private passenger auto and homeowners insurance; specialty auto products, including motorcycle, trailer, motor home, and off-road vehicle insurance; other personal ...
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
ALL vs INCY — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $922.0M | $1.3B |
| Net Profit | $2.5B | $303.3M |
| Gross Margin | — | — |
| Operating Margin | -1400.3% | 23.7% |
| Net Margin | 266.6% | 23.8% |
| Revenue YoY | 7.2% | 20.9% |
| Net Profit YoY | — | 91.7% |
| EPS (diluted) | $9.25 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $922.0M | $1.3B | ||
| Q4 25 | $17.3B | $1.5B | ||
| Q3 25 | $17.3B | $1.4B | ||
| Q2 25 | $16.6B | $1.2B | ||
| Q1 25 | $16.5B | $1.1B | ||
| Q4 24 | $16.5B | $1.2B | ||
| Q3 24 | $16.6B | $1.1B | ||
| Q2 24 | $15.7B | $1.0B |
| Q1 26 | $2.5B | $303.3M | ||
| Q4 25 | $3.8B | $299.3M | ||
| Q3 25 | $3.7B | $424.2M | ||
| Q2 25 | $2.1B | $405.0M | ||
| Q1 25 | $595.0M | $158.2M | ||
| Q4 24 | $1.9B | $201.2M | ||
| Q3 24 | $1.2B | $106.5M | ||
| Q2 24 | $331.0M | $-444.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 92.0% | ||
| Q3 25 | — | 92.8% | ||
| Q2 25 | — | 93.5% | ||
| Q1 25 | — | 93.0% | ||
| Q4 24 | — | 92.5% | ||
| Q3 24 | — | 92.4% | ||
| Q2 24 | — | 92.7% |
| Q1 26 | -1400.3% | 23.7% | ||
| Q4 25 | — | 22.3% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 43.6% | ||
| Q1 25 | — | 19.5% | ||
| Q4 24 | — | 25.6% | ||
| Q3 24 | — | 12.8% | ||
| Q2 24 | — | -45.8% |
| Q1 26 | 266.6% | 23.8% | ||
| Q4 25 | 22.1% | 19.9% | ||
| Q3 25 | 21.7% | 31.1% | ||
| Q2 25 | 12.7% | 33.3% | ||
| Q1 25 | 3.6% | 15.0% | ||
| Q4 24 | 11.7% | 17.1% | ||
| Q3 24 | 7.2% | 9.4% | ||
| Q2 24 | 2.1% | -42.6% |
| Q1 26 | $9.25 | $1.47 | ||
| Q4 25 | $14.24 | $1.46 | ||
| Q3 25 | $13.95 | $2.11 | ||
| Q2 25 | $7.76 | $2.04 | ||
| Q1 25 | $2.11 | $0.80 | ||
| Q4 24 | $7.07 | $0.90 | ||
| Q3 24 | $4.33 | $0.54 | ||
| Q2 24 | $1.13 | $-2.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $31.6B | $5.6B |
| Total Assets | $124.0B | $7.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $4.9B | $3.1B | ||
| Q3 25 | $8.7B | $2.5B | ||
| Q2 25 | $9.6B | $2.0B | ||
| Q1 25 | $6.5B | $1.9B | ||
| Q4 24 | $4.5B | $1.7B | ||
| Q3 24 | $7.0B | $1.3B | ||
| Q2 24 | $5.3B | $987.3M |
| Q1 26 | — | — | ||
| Q4 25 | $7.5B | — | ||
| Q3 25 | $8.1B | — | ||
| Q2 25 | $8.1B | — | ||
| Q1 25 | $8.1B | — | ||
| Q4 24 | $8.1B | — | ||
| Q3 24 | $8.1B | — | ||
| Q2 24 | $8.1B | — |
| Q1 26 | $31.6B | $5.6B | ||
| Q4 25 | $30.6B | $5.2B | ||
| Q3 25 | $27.5B | $4.7B | ||
| Q2 25 | $24.0B | $4.2B | ||
| Q1 25 | $22.1B | $3.7B | ||
| Q4 24 | $21.4B | $3.4B | ||
| Q3 24 | $20.9B | $3.2B | ||
| Q2 24 | $18.6B | $3.0B |
| Q1 26 | $124.0B | $7.3B | ||
| Q4 25 | $119.8B | $7.0B | ||
| Q3 25 | $120.4B | $6.3B | ||
| Q2 25 | $115.9B | $5.8B | ||
| Q1 25 | $115.2B | $5.7B | ||
| Q4 24 | $111.6B | $5.4B | ||
| Q3 24 | $113.7B | $5.0B | ||
| Q2 24 | $108.4B | $4.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.37× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
